Business report

Global Gastrointestinal Therapeutics Strategic Business Report 2022: Market is expected to reach $84.4 billion by 2027 – Crohn’s disease is expected to be worth $16.3 billion –

DUBLIN–()–The “Gastrointestinal Therapeutics: Global Strategic Business Report” report has been added to from offer.

Global Gastrointestinal Therapeutics Market to Reach $84.4 Billion by 2027

The global gastrointestinal therapeutics market estimated at US$61.2 billion in 2020 is expected to reach a revised size of US$84.4 billion by 2027, growing at a CAGR of 4.7% on the analysis period 2020-2027.

Crohn’s disease, one of the segments analyzed in the report, is expected to register a CAGR of 4.6% and reach US$16.3 billion by the end of the analysis period. Given the ongoing post-pandemic recovery, Ulcerative Colitis segment growth is readjusted to a revised CAGR of 4.8% for the next 7-year period.

The US market is estimated at $16.5 billion, while China is expected to grow at a CAGR of 7.5%

The gastrointestinal therapeutics market in the United States is estimated to be worth US$16.5 billion in 2020. China, the world’s second largest economy, is expected to reach a projected market size of US$17.5 billion from by 2027, with a CAGR of 7.5% over the analysis period 2020 to 2027.

Other notable GeoMarkets include Japan and Canada, each predicting growth of 2.7% and 3.7% respectively over the 2020-2027 period. In Europe, Germany is expected to grow at a CAGR of approximately 3.4%. Led by countries like Australia, India, and South Korea, the Asia-Pacific market is expected to reach US$11.4 billion by 2027.

The GERD segment will register a CAGR of 5.1%

In the global GERD segment, the United States, Canada, Japan, China and Europe will drive the estimated CAGR of 5.1% for this segment. These regional markets representing a combined market size of US$5.1 billion in 2020 will reach a projected size of US$7.1 billion by the end of the analysis period.

China will remain among the fastest growing markets in this group of regional markets. Latin America will grow at a CAGR of 5.5% during the analysis period.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors

  • Market presence in multiple geographies – Strong/Active/Niche/Trivial

  • Peer-to-peer collaborative online interactive updates

  • Access to digital archives and a research platform

  • Free updates for one year

Main topics covered:




  • Overview of the influencer market

  • Global Market Trajectories

  • Gastrointestinal Therapeutics – Percentage of market share of the main global competitors in 2022 (E)

  • Impact of Covid-19 and a looming global recession

  • Competitive Market Presence – Strong/Active/Niche/Trivial for Gamers Worldwide in 2022 (E)


  • AbbVie, Inc.

  • Alfa Wassermann, Inc.

  • Allergan PLC

  • Amgen, Inc.

  • Anterogen Co., Ltd.

  • Ardelyx, Inc.

  • Astellas Pharma, Inc.

  • Astellas Pharma, Inc.

  • AstraZeneca PLC

  • Biogene, Inc.

  • Celgene Company

  • Cosmo Pharmaceuticals SA

  • Drais Pharmaceuticals, Inc.

  • Eisai Co., Ltd.

  • Eli Lilly and company

  • Enlivex Therapeutics Ltd.

  • F. Hoffmann-La Roche SA

  • Ferring Pharmaceuticals, Inc.

  • FFPharma

  • Galapagos NV

  • Gilead Sciences, Inc.

  • GlaxoSmithKline, Inc.

  • Hutchison MediPharma Limited

  • Immune Pharmaceuticals, Inc.

  • Index Pharmaceuticals Holding AB

  • Ironwood Pharmaceuticals, Inc.

  • Johnson & Johnson

  • Kissei Pharmaceutical Co., Ltd.

  • Kyowa Hakko Kirin Co., Ltd.

  • Lexicon Pharmaceuticals, Inc.

  • Lipid Therapeutics GmbH

  • Meda AB

  • Merck & Co., Inc.

  • Mesoblast Ltd.

  • Mitsubishi Tanabe Pharma Corporation

  • Mochida Pharmaceutical Co., Ltd.

  • Morphotec, Inc.

  • Neovacs SA

  • Nestlé SA

  • Norgine B.V.

  • Novartis AG

  • Pfizer, Inc.

  • Procter & Gamble Company, The

  • Qu Biologics Inc.

  • RedHill Biopharma Ltd.

  • Sterna Biologicals GmbH & Co. KG

  • Synthetic Biologics, Inc.

  • Takeda Pharmaceutical Co., Ltd.

  • TiGenix SA

  • Tillotts Pharma SA

  • TopiVert Ltd.

  • UCB SA





For more information on this report, visit